|
|
| home about us advertise with us downloads links privacy contact us site map copyright policy |
| ||
untitledNearly 1.5 million Americans suffer a heart attack every year, with 45 percent of these attacks occurring in people under the age of 65. St. Mary's expert cardiovascular team can help to ensure that you're not one of those statistics. From diagnosis to treatment and rehabilitation, St. Mary's delivers advanced cardiac services and works hard to improve the overall health of our communities. If so, you and more than 100 million Americans are now trying to keep those often bold and hastily conceived prom-ises. Commitments associated with healthier living appear on nearly everyone's listand also are some of the first resolutions to drop off by about this time of the year. From exercising and laughing more to quitting smoking, you can start these seven tips today--regardless of your age--and begin to see and feel the benefits in no time at all. At St. Mary's, we're building upon that type of success by challenging Knoxville employers, educators, civic and community officials,AstraZeneca Presentation Gastrointestinal R&D Update 2000! AstraZeneca GI Franchise Dr Hans Glise Vice President, Head of GI Area Irritable Bowel Syndrome (IBS) Inflammatory Bowel Disease (IBD) Inflammatory Bowel Disease (IBD) Irritable Bowel Syndrome (IBS) Inflammatory Bowel Disease (IBD) D:\nternet\nbox0088glaxosmithklinecomplaintAct, as amended, 15 U.S.C. § 18, and Section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C. § 45, and it appearing to the Commission that a proceeding in respect thereof would be in the public interest, hereby issues its Complaint, stating its charges as follows: 1. 2. 3. " Ceftazidime" means any product that contains any form or formulation of the compound ceftazidime, any of its constituent elements, active ingredients or intermediaries, and all rights relating to the research, development, manufacture and sale of any such Product. Ceftazidime is a semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for pseudomonas and other gram-negative infections in hospitalized patients. 4. "5HT-3 antiemetic drug" means any 5HT-3 receptor antagonist prescription pharmaceutical compound indicated for the prevention and treatment of nausea and vomiting associated with medical treatment, including chemotherapy, radiation therapy, orSBMS CPD DetailsOxidative damage in the aetiology and pathogenesis of other conditions: cataract, retrolental fibroplasia, inflammatory disease, rheumatoid arthritis, emphysema, adult respiratory distress syndrome, inflammatory bowel, pre-eclampsia, some neurodegenerative diseases, traumatic injury to the brain and spinal cord, ischemia-reperfusion injury (e.g. myocardial infarction, stroke, rheumatoid arthritis), ageing etc. Physiological influences of non-starch polysaccharides: plasma cholesterol lowering, modification of the glycaemic response, large bowel function, nutrient availability. Diet and gastrointestinal disease epidemiology Colorectal cancer and diet: meat, non-starch polysaccharides, starch, fact, fruit and vegetables - phytoprotectants, antioxidants etc. Nutritional support for the gut: glutamine, dietary enzyme supplementation etc. Nutritional management of coeliac disease, Crohn's disease, constipation, irritable bowel syndrome, diverticular Diet in the aetiology ofWho Is Likely to GetIt kills about 55,000 Americans each year. It is most common in people who are 50 years old or older. Doctors do not know exactly what causes colorectal cancer. However, there are some things that increase your risk. - You are 50 years old or older - You or a family member had polyps or colorectal cancer before; Some types of cancer of the ovary, uterus, or breast are hereditary. If you or someone in your family has had these cancers you may be at higher risk for colorectal cancer. Be tested at a younger age if you or a family member had polyps or colorectal cancer before; colon diseases such as "Ulcerative Colitis", "Crohn's Disease" or "Irritable Bowel Syndrome"; or hereditary kinds of cancer of the ovary, uterus, or breast.989Effect of colonic pacing on the clinical manifestations of the IBS 5. ABSTRACT The treatment of the irritable bowel syndrome (IBS) is not entirely satisfactory as the exact cause of the condition has not been revealed. We have demonstrated in a recent study that the IBS exhibited a "tachyarrhythmic" electromyographic pattern; the wave rhythm was irregular and wave variables were higher than those of the healthy volunteers. We suggested that a disorder of the colonic pacemaker discharges these abnormal waves thereby causing the motor disorders of IBS. In another study, we determined the colonic pacing parameters needed to modulate the disordered pacemaker. In the current communication we investigated the effect of colonic pacing, using these parameters, on the EMG activity of the sigmoid colon (SC) and on the clinical manifestations of patients with IBS. The patients complain of abdominal pain with or without alterations in bowel habits but do not show anyRésumé_EDuring the last decades, working conditions and work environment have dramatically changed in most industrialized societies (Paoli, 1997, 2001). Economic, structural and organizational changes have become more and more common, resulting in privatization, successive merging, downsizing, and even bankruptcies. Although the overall unemployment rate has remained relatively unchanged in the recent years in the European Region (International Labor Office, 2004), some economic sectors have particularly suffered from an increased unemployment rate. The structural and organizational changes have contributed to the phenomenon of `casualisation of labor'. The somatic strains were functional dyspepsia and irritable bowel syndrome, two functional gastrointestinal disorders, and somatization and somatoform disorder which focus on medically unexplained symptoms. Functional dyspepsia and irritable bowel syndrome where diagnosed on the basis of 9 and 10 questions respectively which wereGastro_2003_22.2a oral 2.2b enteral 2.2c parenteral 2.3 The gastroenterology nurse has a general awareness of food, over-the-counter drugs, herbal remedies or alternative therapies known to have an effect on the gastroenterological system or to interact with other drugs. 3.1c colonoscopy 3.1d enteroscopy 3.1e small bowel capsule study 3.1f sigmoidoscopy 3.1g anoscopy 3.1h endoscopic ultrasound 3.1i. manometry 3.1j 24-hour PH monitoring 3.1k specimen collection 3.1l diagnostic imaging 3.2 The gastroenterology nurse demonstrates a general understanding of the significance of diagnostic test results: 3.3 The gastroenterology nurse describes the general procedure and basic principles (including equipment, indications, contraindications, patient preparation and potential complications) for the following therapeutic interventions: Hemostasis and Tumour Ablation 3.3a variceal therapies 3.3b tamponade 3.4 The gastroenterology nurse demonstrates knowledge of the common types of surgery used forar2005_05Takeda undertakes global research and development with the aim of creating new drugs that are both medically and socially meaningful. Takeda has until now conducted research and develop-ment, from target discovery to drug creation, at research centers in Tsukuba and Osaka in Japan. In March 2005, however, Takeda secured its first research base outside Japan with the acquisition of a U.S. bioventure. Takeda is devoted to utilizing this global research network to deliver highly innovative pharmaceuticals as quickly as possible. PROMOTING PATIENT-FOCUSED RESEARCH Takeda is taking proactive steps to strengthen its pipeline. This involves accurately understanding patient needs and focusing management resources on the Company's four core therapeutic areas: lifestyle-related diseases, cancer and urological diseases, central nervous system (CNS) diseases, and life-cycle management of drugs for digestive system diseases. concentration, emotional depression, irritability, and anxiety.The Royal College of General Practitioners would like to express its thanks to these individuals. Key messages Digestive problems are common in general practice The general practitioner has a central role in the diagnosis and management of digestive problems in primary care. Dyspepsia and gastro-oesophageal reflux disease (GORD) are common conditions, affecting around 28% of the population Prevention and early treatment of colorectal cancer are priorities of the Departments of Health because Digestive problems are common in general practice. The general practitioner has a central role in the diagnosis and management of digestive problems in primary care. This RCGP Curriculum Statement on Digestive Problems covers conditions of the entire gastrointestinal tract, including the liver, pancreas, gall bladder and perianal area. Intervene urgently when patients present with an acute abdomen Recognise and respond urgently to red flag symptoms, which may indicate GI cancer INCOMING STUDENT: This form is to be completed prior to your arrival on campus. It requires a brief health history, insurance documentation, a physical exam and a record of your immunizations. To assure that your records are received and reviewed prior to your arrival, please return your completed form to the Student Health Center no later than July 1st. Note: All full time undergraduates must have health and accident insurance. Saint Joseph's University Students may enroll in a Student Health Care Program which offers comprehensive coverage at minimum cost. CONSENT FOR TREATMENT (required for students under 18): I hereby give consent for my minor child, to receive routine care through the SJU Health Center and in the event of an EMERGENCY, give permission to the Health Center and its affliliated hospital to secure for this child appropriate treatment. CONSENT FOR TREATMENT (students over 18): In the event of an EMERGENCY, I hereby give permission to the SJU Health 32916_43-96This section presents detailed information on the utilization and cost of the top 25 therapy classes for 2004. Components of trend have been analyzed for each class. Also included are market-share trends for the major drugs within the class and projected trends for the class as a whole. Because specialty drugs have been removed from the calculations in some therapy classes, trends for 2002 have been recalculated. Drugs that are in the pipeline and patent expirations that have significant potential to affect a specific class in the next several years are also presented. While another therapy class is unlikely to dislodge the antihyperlipidemics from their top perch in the foreseeable future, upcoming events probably will have an impact on their drug trend. These events, combined with significant marketing budgets for existing drugs and the aging of the population, will likely result in continued utilization growth. The most significant new drug story in this classMental Health Manual updateThis update of the ICD-10-AM Mental Health Manual makes the codes consistent with those in ICD-10-AM Fourth Edition (July 2004). It is intended to be incorporated into the first edition of the manual or as a companion document and cannot be used by itself. The alterations are listed by section and page numbers and contain instruction to add or delete text as required. Text to be added is indicated by underline. Text to be deleted is indicated by strikethrough. The NCCH is grateful for the comments received for changes to be presented in a second edition of the ICD-10-AM Mental Health Manual. Comments from users for current and future changes have been reviewed and implemented in this update. Further user feedback will be invited to inform the review and expert clinical advice will be sought to verify all suggested amendments. This will ensure that the revision presents a user-friendly format for the next edition of the ICD-10-AM Mental Health Manual.New DrugsPeople with irritable bowel syndrome (IBS) have a lower gastrointestinal (GI) tract that might be more sensitive and work more slowly than it should, causing abdominal pain and discomfort, bloating, and altered bowel function (constipation and/or diarrhea). Tegasrod maleate (Zelnorm, Novartis) activates sero-tonin-4 receptors, which stimulates peristaltic reflex and normalizes the impaired motility in the GI tract. Disagree about Benzodiazepine In a survey of 93 patients and 25 physicians, University of Toronto researchers found a major disconnect: patients perceived higher benefits and lower risks with benzodiazepines than physicians did. According to the investigators, the evidence on benzodiazepine use in older patients with insomnia is "either inconclusive, conflicting, or anecdotal." They say, for instance, that no prospective studies have looked at the efficacy of benzodiazepine use for insomnia for longer than one month, even though many older patients might be taking0471490881-2Contents PREFACE, ix ACKNOWLEDGMENTS, xi HOW TO USE THIS BOOK, 1 Burns (including Sunburn), 110 Cancer, 113 Candidiasis (Thrush and Yeast Infection), 125 Cardiovascular Disease, 130 Carpal Tunnel Syndrome (CTS), 139 Cataracts, 143 Cholesterol, High, 147 Chronic Fatigue Syndrome (CFS), 154 Common Cold, 161 Constipation, 166 Cough, 171 Crohn's Disease, 176 Cystitis (see BLADDER INFECTION) Irritable Bowel Syndrome, 344 Premenstrual Syndrome (PMS), 438 Syndrome X, 498 TMJ (Temporomandibular Joint) Syndrome,NewProductsBased on these annual projections, PMPY AWP costs are estimated to grow by 94.3 percent over the next five years from $592.05 in 2002 to $1,150.14 in 2006. A key assumption underlying these projections is the inflation rate that will occur through 2006. At the time this Report was written, we have no reason to think that future price increases for prescription drugs will be much differ-ent than the 5+ percent seen over the past several years. Consequently, Express Scripts projects that inflation will generally be 6 percent in 2002, 5.5 percent in 2003 and 5 percent annually from 2004 through 2006. The relationship between our overall PMPY cost projections and our inflation assumptions is depicted graphically in Figure 4. (01/02-05/06 projected) In addition to inflation, other factors in the therapy class specific projections are the aging of the population, anticipated utilization and product mix, introduction of new products and products losingFL01_ARMDuring fiscal 2001 net current assets increased by $226,388,000. Increases in cash, accounts receivable, inventories and accrued expenses resulted primarily from increases in sales, particularly CelexaTM. Celexa (citalopram HBr) is the Company's selective serotonin reuptake inhibitor ("SSRI") for the treatment of depression. Inventory levels have increased to meet the growing demand for Celexa. During the year, the Company increased its investment in long-term marketable securities in order to receive more favorable rates of return on invested funds. The increase in license agreements, product rights and other intangible assets was due to several late-stage product license agreements entered into by Forest during the period. These agreements include dexloxiglumide for the treatment of irritable bowel syndrome, lercanidipine for the treatment of hypertension and memantine for the treatment of Alzheimer's Disease and neuropathic pain. Sales of Infasurf®, Forest'sFL01_ARLThe down phase of its mood swings inevitably involves undervaluing real value just like the manic phase involved overvaluing speculations. The value market looks for good old-fashioned earnings. At Forest, we believe our job as managers is to continue to create real and increasing value by achieving real and sustainable earnings growth, despite stock market gyrations. And we have to keep communicating our results and our strategies to investors so that we will be adequately appreciated when the market is in the mood to fully appreciate value. It is the sale of products at a profit, and the prospect of more products and more sales and more profits that determines real value. And that is where we excel, more this year than ever before. These results confirm that Forest, without assistance from anyone, can promote and sell its products on a scale comparable to the most successful companies in our industry. ML3000 is our COX/lipoxygenase inhibitor forTC4 T of C 1TABLE OF CONTENTS Revised August 20, 2003 Editorial Board Authors 8. Drug Withdrawal Syndromes, Claudio A. Naranjo 26. Acute Coronary Syndromes, Michelle Graham 48. Inflammatory Bowel Disease, Brian G. Feagan 49. Irritable Bowel Syndrome, W. Grant Thompson 54. Chronic Fatigue Syndrome, Elizabeth MannTable of Contents with Roman numeralsTable of Contents Patient Self-Care. Helping Patients Make Therapeutic Choices. Editorial Board vi Authors vii Practitioner Review Board x List of Illustrations xi 25. Irritable Bowel Syndrome, Peter Thomson 269 51. Dysmenorrhea and Premenstrual Syndrome, Thomas E. R. Brown and Christinne Campbell 684gregoryCollege London. Following the completion of his doctorate, Dr Gregory began his post-doctoral research training in functional magnetic resonance imaging of visceral sensation. Upon completing a Neurosciences degree at the University of Central Lancashire, Dr Gregory went on to study for a PhD at the Institute of Psychiatry, King's College London in Psychology and Neuroimaging. Since 1991, he has been consistently involved in research and is currently a Medical Research Council Clinician Scientist. His major research interest is to study the human brain gut axis using functional brain imaging techniques. He is currently studying factors that modulate the brain processing of gut sensation in health and in patients with functional gastrointestinal disorders. Following his initial clinical training in Pakistan, Dr Aziz trained in General Medicine and Gastroenterology in the UK. Patients and Health Resources In clinical practice, a common functional disorder of the GI tractMMH-DDC-0203The Digestive Disease Center at Memorial Hermann Hospital provides a unique opportunity for fellows in training to see patients referred to this outpatient facility regarding specific issues related to gastrointestinal problems that often include complex cases, referrals from outside physicians, and second or third opinions regarding diagnosis and management. Working one-on-one with faculty in the Clinic provides close interaction between fellows and staff in the effective analysis of a very wide range of gastrointestinal problems, and the effective management and efficiency of operations related to outpatient practice. Fellows rotate through the Digestive Disease Center six weeks during the first year, fourteen weeks during year two, and eight weeks during the last year. Some of the more common conditions encountered are: irritable bowel syndrome, inflammatory bowel disease, motility disorders, malabsorption, and screening/surveillance for neoplasia orrST04Bs_ukStudy of the relationship between job stress, psychosocial variables, and different dimensions of physical health. Catholic University of Leuven - KUL From the scientific literature in health psychology one may conclude that chronic (job) stress has a negative influence on health status. It also appears that psychosocial dimensions are an important factor for the development of health complaints. Keeping this in mind, we have tried to figure out how the interaction between job stress and a number of psychosocial variables could be related to subjective health dimensions. Studies in psychoneuroimmunology have shown that stress and also depression have an impact on the immune system. This was the starting point for our own immunological study. A high level of job stress was associated with a higher prevalence of several somatoform disorders, such as chronic fatigue syndrome, irritable bowel syndrome (functional lower abdominal complaints), and fibromyalgia (diffuse1 | 2 | 3
| 4 | 5 | 6
| 7 | 8 | 9
| 10 | 11 | 12
| 14 | 15 | | ||
